[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adverse-events\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adverse-events":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,70,108,137,165,197,226],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100501048","cricket-critical-events-in-anaesthetised-kids-undergoing-tracheal-intubation-100501048",false,"NCT05804188","CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation","CRICKET","Inclusion Criteria:\n\n* All paediatric patients requiring tracheal intubation, performed by the anaesthesia team for procedures or interventions requiring general anaesthesia\n* Patients from 0 - 16 years of age.\n* Informed or general consent given, according to the relevant ethics committee statement.\n\nExclusion Criteria:\n\n* Refusal to give consent or withdrawal of consent if such is required by the relevant ethics committee.\n* Patients \\>16 years","ALL","16 Years",{"count":19,"type":20},105000,"ESTIMATED","30 Days","OBSERVATIONAL","The investigators' overall objective is to assess the incidence of critical events related to tracheal intubation at all international study sites. Furthermore, the study will investigate the used intubation techniques and identify possible improvement measures to increase patient safety.",[25,26],"Intubation Complication","Adverse Events",[28,29,30,31,32],"Intubation, Intratracheal","Anesthesiology","Difficult Airway","Critical events","Pediatrics","RECRUITING","2026-05-09",{"date":36,"type":37},"2026-05-12","ACTUAL",{"date":39,"type":37},"2024-01-08",{"date":41,"type":20},"2026-07",{"name":43,"class":44},"Thomas Riva","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100525087","prospective-assessment-project-of-airway-management-related-incidents-in-adult-anaesthesia-care-papaya-iii-100525087","NCT06117176","Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care PAPAYA III","Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care (PAPAYA III) - A European Multicentre Cross-sectional Observational Study","PAPAYA-III","Inclusion Criteria:\n\n* All adult patients requiring airway management under anaesthesia care for elective, semi-elective, urgent or emergency diagnostic procedures or interventions. Airway management includes awake and asleep tracheal intubation, insertion of supraglottic airway devices, and face mask ventilation.\n* Patients older than 18 years of age\n* Informed consent given or general consent in place, according to local ethics committee requirements.\n\nExclusion Criteria:\n\n* Refusal to give consent or withdrawal of consent.\n* Patients \\\u003C18 years.","18 Years",{"count":55,"type":20},40000,"The overall objective of the study is to evaluate and analyze major and minor incidents during airway management in adults under anaesthesia care at all study sites. The patient characteristics, type of airway management is recorded and if airway management-related incidents occur, they are analyzed in more detail to improve patient safety in the future.",[58,26],"Airway Complication of Anesthesia",[28,29,30,31],"2026-03-02",{"date":62,"type":37},"2026-03-04",{"date":64,"type":37},"2025-02-01",{"date":66,"type":20},"2027-03",{"name":68,"class":44},"Insel Gruppe AG, University Hospital Bern",5,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100587534","amino-acid-infusion-in-kidney-transplant-recipients-100587534","NCT06929637","Amino Acid Infusion in Kidney Transplant Recipients","The Effect of Amino Acid Infusion on Early Graft Function After Kidney Transplantation","AID-KT","Inclusion Criteria:\n\n* Adult patients (≥18 years) undergoing deceased or living donor kidney transplantation\n* First-time kidney transplant recipients\n* No known allergy or contraindication to amino acids\n* Stable hemodynamic status post-transplant\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients requiring immediate dialysis post-transplant\n* Multi-organ transplant recipients\n* Severe hepatic dysfunction (Child-Pugh C)\n* Uncontrolled infection or sepsis\n* Malignancy within the past 5 years (except non-melanoma skin cancer)\n* Prior participation in conflicting clinical trials",{"count":79,"type":20},100,"INTERVENTIONAL",[82],"NA","The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.",[85,86,87,88,89,26],"Short-term Graft Function","Metabolic Effects","Nutritional Effect","Immunological &Amp; Inflammatory Markers","Safety",[91,92,93,94,95,96],"kidney transplantation","aminoacids","delayed graft function","diabetes mellitus","acute graft rejection","estimated glomerular filtration rate","NOT_YET_RECRUITING","2025-04-08",{"date":100,"type":37},"2025-04-16",{"date":102,"type":20},"2025-09-15",{"date":104,"type":20},"2029-01-01",{"name":106,"class":44},"University Hospital, Martin",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":80,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":107},"100584605","phase-2-electroacupuncture-for-preventing-adverse-events-of-cancer-immunotherapy-100584605","NCT06891521","Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy","Electroacupuncture for Preventing Adverse Events Associated With Cancer Immunotherapy: A Prospective, Multicenter, Open-Label, Single-Arm Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, any gender, any nationality.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n3. A definitive diagnosis of malignant tumor confirmed by pathology, and no previous treatment with PD-1\u002FPD-L1 inhibitors.\n4. Patients who are receiving their first treatment with PD-1\u002FPD-L1 inhibitors monotherapy, PD-1\u002FPD-L1 inhibitors combined with anti-angiogenic agents, or combined chemotherapy.\n5. Expected survival of more than 3 months.\n6. Normal bone marrow and organ function.\n7. Premenopausal women must use adequate contraception.\n8. Written informed consent obtained from the patient prior to enrollment.\n\nExclusion Criteria:\n\n1. Patients who have previously received or are currently receiving immunotherapy monotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with targeted therapy.\n2. Patients who have undergone acupuncture, radiotherapy, or surgery within 4 weeks prior to the start of treatment.\n3. Patients who have received any dose of systemic corticosteroid treatment within 72 hours prior to Day 1 of Cycle 1.\n4. Patients with active systemic autoimmune diseases within the past 2 years (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with a history of vitiligo or asthma in childhood who have been in complete remission with no intervention in adulthood may be included; subjects requiring bronchodilator medical intervention should be excluded), diagnosed with immunodeficiency or treated with immunosuppressive therapy within the past week, human immunodeficiency virus (HIV) (+), history of non-infectious pneumonia treated with glucocorticoids, pneumonia, active tuberculosis, active hepatitis B or C virus infection, or currently undergoing any systemic treatment for active infections.\n5. Significant abnormal laboratory values (platelet count, absolute neutrophil count, free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone(TSH), adrenocorticotropic hormone (ACTH), morning cortisol, glycated hemoglobin (HbA1c), C-peptide, autoantibodies, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, prothrombin time\u002Finternational normalized ratio (PT\u002FINR), serum bilirubin, amylase, lipase, CRP).\n6. Skin diseases or inflammatory skin reactions that may interfere with clinical trial outcomes.\n7. Patients who have developed lymphedema at the site of acupuncture stimulation after receiving any acupuncture treatment.\n8. Patients who fear electroacupuncture stimulation or are allergic to stainless steel needles.\n9. Patients with psychiatric disorders, or those taking any antipsychotic or antidepressant medications.\n10. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss.\n11. Patients with diabetes.\n12. Any other diseases, metabolic disorders, physical examination results, or clinical laboratory findings that raise reasonable suspicion of a disease or condition that may affect the interpretation of the outcomes or put the participant at high risk for treatment complications.\n13. Pregnant or breastfeeding women, or women planning to become pregnant during the study period.\n14. Severe medical or psychiatric conditions.\n15. Any patient deemed unsuitable for enrollment by the investigator.","80 Years",{"count":117,"type":20},123,[119],"PHASE2","This study aims to investigate the preventive effects of electroacupuncture on immune-related adverse events (irAEs) in patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The study will evaluate the efficacy, safety and mechanisms of electroacupuncture in preventing irAEs in a multicenter setting.",[122,26],"Cancer",[124,125,126,127],"Electroacupuncture","immunotherapy","immune-related adverse events (irAEs)","malignant tumors","2025-03-17",{"date":130,"type":37},"2025-03-24",{"date":132,"type":20},"2025-03-20",{"date":134,"type":20},"2028-06-01",{"name":136,"class":44},"Qinghai Red Cross Hospital",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100584496","study-of-the-association-between-fatigue-experienced-by-patients-and-the-specific-side-effects-of-cart-cells-during-the-first-month-after-administration-for-non-hodgkins-lymphoma-100584496","NCT06890091","Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma","Etude de l'Association Entre la Fatigue Ressentie Par Les Patients et Les Effets Secondaires spécifiques Des CART Cells, au Cours du Premier Mois après l'Administration Pour un Lymphome Non Hodgkinien","CAR-TIGUE","Inclusion Criteria:\n\n* Adult (age\\> 18year old)\n* Person hospitalised for treatment with CAR-T Cells for non-Hodgkin's lymphoma.\n* Person able to understand and read the French language.\n\nExclusion Criteria:\n\n* Patient under legal protection\n* Opposition to research",{"count":79,"type":20},"The incidence of cancer in 2023 is estimated at 433136 cases, according to INCa. Haemopathies account for 12% of these new cases of cancer cases of cancer, and around two-thirds are lymphoid haemopathies, in particular lymphomas. There are many treatments available for lymphoma. However, the arrival in France in 2018 of immunotherapy treatments such as CAR-T Cells have changed the paradigm of treatment options for certain non-Hodgkin's lymphomas. In these treatments can have both short-term and long-term adverse effects and long-term adverse effects. During hospitalisation for the administration of CAR-T Cells, acute side effects include CRS and ICANS. There is also another complication very specific to this treatment that has been observed in patients: cytopenias. This is despite the fact that one of the symptoms frequently mentioned and felt by patients during the first month after month after treatment is fatigue. Despite numerous studies on the prevalence of fatigue, healthcare professionals often underestimate this symptom. Nurses, and in particular the advanced practice nurse have a crucial role to play in assessing fatigue. The EORTC scale QLQ-FA12 is a multidimensional scale which assesses the physical emotional and cognitive dimensions of fatigue. The theory of symptom management, which was developed in 1994 by the California College of Nursing in San Francisco, is a relevant framework for understanding fatigue in patients. This theory places the patient's experience at the centre of care. This holistic approach provides a detailed framework for understanding this symptom. \"According to the theoretical model, measuring the symptom is an important step and characterising it is an essential element in better targeting the actions to be taken\". Although CAR-T Cell therapy is innovative and allows long-term remissions, it is important to evaluate and understand how patients live with this treatment. To our knowledge, few studies have been carried out on quality of life, particularly regarding fatigue, following the first month of CAR-T Cell administration. The research question we will address in this study is: \"Is there an association between the side effects of CAR-T Cell treatment and the state of fatigue in patients receiving this treatment for non-Hodgkin's lymphoma during the first month?\"",[148,149,150,26],"Fatigue Symptom","Lymphoma Non-Hodgkin","Chimeric Antigen Receptor T-cell Therapy",[152,153,154,155,149,156],"Fatigue","CAR-T cells","Chimeric antigen receptor","Adverse events","Nurse practitionners",{"date":158,"type":37},"2025-03-21",{"date":160,"type":20},"2025-04-01",{"date":162,"type":20},"2026-05-01",{"name":164,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":172,"minAge":53,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":80,"phases":176,"briefSummary":177,"conditions":178,"keywords":184,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100572471","the-use-of-virtual-reality-technology-during-oocyte-retrieval-for-in-vitro-fertilization-100572471","NCT06733701","The Use of Virtual Reality Technology During Oocyte Retrieval for in Vitro Fertilization","The Use of Virtual Reality Technology During Oocyte Retrieval for in Vitro Fertilization: a Randomized Controlled Pilot Study","Inclusion Criteria:\n\n\\- All adults undergoing their first oocyte retrieval\n\nExclusion Criteria:\n\n* severe visual impairment\n* contraindications to using VR technology according to manufacturer specifications including:\n* severe motion sickness\n* epilepsy\u002Fprevious seizure\n* claustrophobia\n* current migraine\n* heart disease\n* use of medical devices such as cardiac pacemaker or hearing aids","FEMALE","43 Years",{"count":175,"type":20},50,[82],"Ultrasound-guided oocyte retrieval (OR) is a short, but oftentimes painful procedure, during which the follicles are punctured trans-vaginally to obtain oocytes for in vitro fertilization (IVF). Conscious sedation is the most commonly used method of pain relief, yet several studies have shown that more than half of women report moderate to high levels of pain and up to 7% of women report extreme or unacceptable levels of pain during OR. Adjuvant virtual reality (VR) therapy has been explored to reduce psychological stress during dental procedures, burn wound care, colonoscopy, as well as other minor procedures. Hence, the purpose of this study is to evaluate the use of VR technology during IVF treatment, particularly with respect to tolerability, patient satisfaction, and pain reduction during oocyte retrieval.",[179,26,180,181,182,183],"Oocyte Retrieval","Procedural Anxiety","Pain Intensity","Satisfaction","Medication Administration",[185,179,186,187],"Virtual Reality","In Vitro Fertilization","Randomized Control Trial","2024-12-13",{"date":190,"type":37},"2024-12-18",{"date":192,"type":20},"2025-01-15",{"date":194,"type":20},"2025-12-31",{"name":196,"class":44},"Mount Sinai Hospital, Canada",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":205,"sex":172,"minAge":53,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100568655","studying-the-senescent-t-cell-features-and-its-relationship-with-the-chemotherapy-efficacy-in-young-tnbc-100568655","NCT06684054","Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC","Study of the Features of Senescent T Lymphocytes Induced by Chemotherapy and Its Relationship with the Efficacy of Neoadjuvant Chemotherapy in Young Triple-negative Breast Cancer Patients, a Single-center, Observational Study.","STFREiYTNBC","Inclusion Criteria:\n\n1. Female, age≤40 years old,\n2. Invasive breast cancer confirmed by pathology, immunohistochemistry showed TNBC (ER-, PR-, HER2-),\n3. Indications for neoadjuvant chemotherapy according to guidelines: tumor diameter \\> 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy.\n\nExclusion Criteria:\n\n1. Stage IV patients or a history of other malignancies,\n2. Having microbial infection or autoimmune disease have not been cured or having HBV, HIV infection,\n3. Having surgery 3 months before enrollment,\n4. Patients with insufficient clinicopathological data,\n5. Does not meet the indications for neoadjuvant chemotherapy or is unwilling to cooperate.",true,"40 Years",{"count":208,"type":20},30,"The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (TNBC) patients.\n\nThe main questions it aims to answer are:\n\n* What are the senescent features of peripheral T lymphocytes in young TNBC patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy?\n* What is the relationship between senescent T cells and adverse events, DFS and tumor infiltrating lymphocytes?\n\n  1. Participants will receive 6 cycles of docetaxel + adriamycin\u002Fepirubicin + cyclophosphamide (TEC\u002FTAC) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy.\n\n2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.\n\n3.Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.",[211,212,26],"T-Cell Dysfunction","Chemotherapy Effect",[214,215,216],"breast cancer","senescence","chemotherapy","2024-11-10",{"date":219,"type":37},"2024-11-12",{"date":221,"type":20},"2025-01-01",{"date":223,"type":20},"2027-12-31",{"name":225,"class":44},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":80,"phases":238,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":107},"100493764","preterm-delayed-cord-clamping-and-early-skin-to-skin-contact-predecess-100493764","NCT05709392","Preterm DElayed Cord Clamping and Early Skin-to-Skin Contact: PreDECESS","Preterm DElayed Cord Clamping and Early Skin-to-Skin Contact","PreDECESS","Inclusion Criteria:\n\nInfants born in gestational weeks 30+0-34+6 through vaginal delivery and admitted to neonatal ward in Sweden.\n\nParents must be able to read Swedish.\n\nExclusion Criteria:\n\nInfants with known disease when an expanded blood volume is expected will be excluded as early cord clamping is recommended (severe anemia, cardiac disease etc).\n\nInfants with known malformations. Infants with severe or moderate asphyxia (defined as APGAR \\\u003C 4 at 5 minutes of age).\n\nInfants where the physician in charge find it inappropriate with delayed cord clamping.\n\nNo time for cord clamping has been registered.","30 Weeks","34 Weeks",{"count":237,"type":20},126,[82],"The PreDECESS trial is a prospective study where that will evaluate a new method taking care of premature infants in gestational weeks 30+0 to 34+6 at birth. The new method includes delayed cord clamping and early skin-to-skin contact with a parent. Two populations of infants with their parents will be compared. Infants taken care of in the traditional way before the new method is introduced, and infants taken care of with the new method when it is being introduced.\n\nPrimary question:\n\nDoes delayed cord clamping and early skin-to skin contact (SSC) lead to better bonding between parents and their infants?\n\nSecondary questions:\n\nAre there any potential adverse effects with delayed cord clamping and early skin-to skin contact (SSC)? Is there a difference in infants level of bilirubin, haemoglobin or proBNP? Is there a difference in infants growth? Is there a difference in infants neurological development? Is there a difference in infants and parents level of stress? Is there a difference in mothers production of breastmilk, frequency of breastfeeding or experience of breastfeeding? Is there a difference in parents mood? How do parents of preterm infants experience giving birth of their preterm baby before and after the introduction of the new method?",[241,242,243,244,26],"Bonding","Stress","Breastfeeding","Child Development",[246],"adverse events","2023-01-23",{"date":249,"type":37},"2023-02-02",{"date":251,"type":37},"2022-12-12",{"date":253,"type":20},"2028-12-11",{"name":255,"class":44},"Ostergotland County Council, Sweden"]